Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $13.65 Analyst target: $37.27 Upside: 173.04%
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. The company is headquartered in Waltham, Massachusetts.
See the full interactive analysis & chart →Informational only — not investment advice.